Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SOMATOTROPIN”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Responses of high-producing dairy cows to long-term treatment with pituitary somatotropin and recombinant somatotropin.

Thirty Holstein cows capable of high milk production were utilized to examine the effects of long-term administration of bovine somatotropin on lactational performance. Treatments were 0 (control), 13.5, 27, and 40.5 mg/day of recombinantly-derived bovine somatotropin and 27 mg/day of pituitary-derived bovine somatotropin. Hormone was injected intramuscularly, once daily beginning at 84 +/- 10 days postpartum and continuing for 188 days. Cows were fed ad libitum a total mixed diet throughout the lactation. Recombinant somatotropin treatments increased average fat-corrected milk yield in a dose-dependent fashion from 23 to 41% over the control production (27.9 kg/day. Pituitary somatotropin (27 mg/day) increased milk production by 16%. Milk lactose, protein, and fat composition was similar for all treatments. Control cows were in positive energy balance throughout the treatment period (4.7 Mcal net energy/day. Initially, the large increase in milk yield with somatotropin treatment caused cows to decrease in energy balance. However, voluntary intake gradually increased, and by week 10 of treatment all somatotropin treatment groups were in positive energy balance. Thus, the gain in body weight over the treatment period was similar for all groups, ranging from 17 to 22%. Gross lactational efficiency (milk per unit of net energy intake) was improved by exogenous somatotropin whether calculated as observed, corrected for body weight changes, or using the theoretical energy requirements for maintenance and milk production. Results are consistent with bovine somatotropin as a homeorhetic control that coordinates an array of physiological processes so that nutrients are partitioned for milk synthesis.

Animals↗

Chromatin structure of the rat somatotropin gene locus and physical linkage of the rat somatotropin gene and skeletal-muscle sodium-channel gene.

Cosmid clones from -32 kb to +74 kb region of the rat somatotropin gene locus were isolated for examination of the chromatin structure in the region from -39 kb to +47 kb by DNase I-sensitivity analysis using rat pituitary-derived GC (somatotropin+, prolactin-), and 235 (somatotropin-, prolactin+) cells, and liver-derived BRL (somatotropin-, prolactin-) cells. DNase I-hypersensitive sites (DHS) specific for somatotropin-producing cells were previously shown to be located exclusively in the -2 kb to +9 kb region [Aizawa, A., Yoneyama, T., Kazahari, K. & Ono, M. (1995) Nucleic Acids Res. 23, 2236-2244]. No other DHS having this specificity was found in the region examined in this study. Except for these and two other DHS located in a cluster in this region, no DHS could be found from -23 kb to +22 kb. DHS having no or less cell-type specificity were scattered about in the -39 kb to -23 kb and +22 kb to +47 kb regions. The polyadenylation site of the human skeletal-muscle Na-channel alpha-subunit gene has been shown present 22 kb upstream from the somatotropin gene [Bennani-Baiti, I. M., Jones, B. K., Liebhaber, S. A. & Cooke, N. E. (1995) Genomics 29, 647-652]. Polyadenylation site of the rat skeletal-muscle Na-channel gene was shown in this study to be at -15.7 kb. The skeletal-muscle Na-channel gene was specifically expressed in skeletal-muscle cells but not in somatotropin-producing cells, and thus the boundary region that ensures the cell-type-specific expression of each gene would appear to be situated between two genes. The region prerequisite for cell-type-specific expression of the rat somatotropin gene was estimated based on the present findings.

Animals↗

Effect of somatotropin on the plasminogen and plasmin system in the mammary gland: proposed mechanism of action for somatotropin on the mammary gland.

Somatotropin exerts a powerful galactopoietic effect when it is administered to dairy cattle. The mechanism by which somatotropin increases milk yield is currently unknown. This study describes the relationship between long-term exogenous somatotropin injections, milk plasmin concentrations, and milk yield. Plasmin is a serine-protease involved in rodent mammary gland involution. Thirty-five control cows were shown to increase milk plasmin concentrations and decrease milk yield as their lactation period advanced past the 2nd mo. In 42 somatotropin injected cows, milk plasmin was maintained at low concentrations, and milking performance was enhanced. Cessation of somatotropin injections at drying off led to a rapid elevation of milk plasmin to control values. Our hypothesis is that somatotropin suppresses plasmin production within the mammary gland, thereby suppressing involution and allowing a persistence of milk production. During a normal lactation, gradually increasing amounts of plasmin within the mammary gland results in the gradual involution process.

Animals↗

A Moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig.

Expression of a Moloney murine leukemia virus (MLV) rat somatotropin fusion gene was examined in a transgenic pig. The fusion gene was integrated in a single site within the genome in a tandem array with approximately eight copies per cell. The integrated in a single site within the genome in a tandem array with approximately eight copies per cell. The integrated MLV-rat somatotropin fusion gene produced high levels of circulating rat somatotropin and resulted in an elevation in the circulating levels of insulin-like growth factor I. Although there was no increase in the rate of growth of the transgenic animal during the rapid growth phase, several phenotypic changes were evident. Skeletal growth was markedly increased and fat deposition was reduced throughout the animal. Blood glucose levels were elevated without ketosis. Northern blot analyses of rat somatotropin RNA revealed that expression of the fusion gene was highest in the spleen, lung, intestine, lymph nodes, and bone marrow. These results show that the MLV promoter can be used to express high levels of biologically active rat somatotropin in transgenic swine.

Animals↗

Monoclonal antibodies to bovine somatotropin: immunoadsorbent reagents for mammalian somatotropins.

Twenty-nine stable hybridoma cell lines secreting monoclonal antibodies to bovine somatotropin (bST) have been produced and characterized. Five of the monoclonal antibodies bind porcine and human somatotropins as well as bST. One of these antibodies was used as a reagent in immunoadsorbent chromatography of recombinant bST or pituitary bST from cell extracts. Following chromatography, the bST preparations retained activity in a rabbit liver radioreceptor assay and in a radioimmunoassay. The immunoadsorbent reagent bound human and porcine somatotropins as well as bovine.

Animals↗

Effect of pituitary somatotropin injections on plasma insulin-like growth factor I and somatotropin profiles in growing heifers.

Effects of daily injections of pituitary-derived bovine somatotropin (bST) for 6 wk were evaluated in 10 growing heifers and compared to 9 placebo-treated control animals. Bovine somatotropin was injected at 50 micrograms/kg BW each day. Body weight and growth, plasma concentrations of insulin-like growth factor I (IGF-I) and somatotropin (ST) were assessed. To measure plasma concentrations of IGF-I, we validated a RIA in which bovine plasma samples were extracted with acid-ethanol, a method that resulted in greater than 90% recovery of IGF-I. Average daily gain was similar during the first 4 wk of the experiment in both control and bST-treated groups; however, at the end of the experimental period (wk 4 and 6) ADG was greater (P less than .05) in bST-treated heifers (1.24 +/- .21 kg/d vs .75 +/- .25 kg/d). Plasma IGF-I from wk 2 to wk 6 were increased in bST-treated animals (452 +/- 97 ng/ml at wk 2; 683 +/- 106 ng/ml at wk 6) compared with controls (293 +/- 62 ng/ml at wk 2 (P less than .01) and 293 +/- 115 ng/ml at wk 6 (P less than .001). Moreover, ADG over the 6-wk experimental period was correlated with mean IGF-I concentrations determined over the same period (r = .55; P less than .01). As expected, mean plasma ST concentrations were increased in bST-injected animals from wk 1 to 6. Gel chromatographic profiles of bovine plasma exhibit a 150,000 molecular weight ST-dependent binding protein-IGF-I complex and a 30,000 molecular weight non-ST-dependent complex. This study validates a method for measuring IGF-I in cattle, and shows a positive relationship among IGF-I and ADG after ST treatment. No correlation, however, was found between plasma ST and growth performance.

Animals↗

Effects of recombinant bovine somatotropin implants on serum concentrations of somatotropin, insulin-like growth factor-I and blood urea nitrogen in steers.

Four cross-bred beef steers averaging 346 kg were used in a 4 x 4 Latin square design to determine the effect of prolonged-release recombinant bovine somatotropin (rbGH) implants on serum concentrations of somatotropin (GH), insulin-like growth factor-I (IGF-I) and blood urea nitrogen (BUN). Recombinant bGH implants of 0, 40, 80 or 160 mg were administered subcutaneously in the tailhead during the 4 trial periods. Each steer received each treatment starting at 06:00 on day 0 with 21 days between treatments. Jugular vein blood samples were collected on days 0, 1, 2 and 3 (4 day time course for GH, IGF-I and BUN) and every 15 min (GH profile) for 6 h on day 3. Serum baseline GH values were higher (P < 0.10) for the 80 and 160 mg treatments than for the control, and peak amplitude was decreased (P < 0.05) by the 40 and 160 mg treatments. There was a trend (P < 0.11) for fewer GH peaks during the 160 mg treatment. Somatotropin concentrations decreased from day 1 to day 3 (P < 0.05) in a linear manner. Serum IGF-I concentrations increased (P < 0.05) in a linear dose-dependent manner from the 0 mg to the 160 mg treatment. BUN concentrations were not significantly altered by rbGH treatment. Results from this experiment indicate that rbGH implants significantly increase serum IGF-I and GH baseline concentrations while suppressing GH peak amplitude in finishing steers.

Animals↗

Partial purification of somatotropin receptors from pig liver: they arise from a single somatotropin receptor messenger RNA transcript.

Specific binding sites for porcine somatotropin (pST) have been identified in pig liver microsomal membranes. Little information, however, is available about the size and number of ST receptor (ST-R) forms present. Therefore, the present study was conducted to characterize ST-R in pig liver using two approaches. In the first set of experiments, cross-linking of [125I]bST (bovine ST) to microsomal membranes, followed by gel electrophoresis under reducing conditions, revealed the presence of a predominant protein of 107 kDa and four other proteins of 71, 52, 40, and 26 kDa. In a second set of experiments, ST-R were partially purified using affinity chromatography. Binding studies indicated that there was an approximately 1,800-fold purification compared to liver homogenate. Two specific proteins of 107 and 40 kDa were detected after crosslinking of [125I]bST to partially purified ST-R. Northern blot analysis revealed that these proteins arise by posttranslational modification of a single 4.2-kilobase somatotropin receptor messenger RNA transcript. Although the present study indicates that several forms of ST-R are present in pig liver, it is not clear what physiological role these different ST-R play in mediating the hepatic effects of pST. It is evident, however, that the smaller proteins are generated from the 107-kDa protein, which is the predominant isoform present in liver microsomal membranes.

Animals↗

Effect of daily replacement therapy with recombinant bovine somatotropin on somatotropin, insulin-like growth factor I, and onset of puberty in beef heifers immunized against growth hormone-releasing factor.

Two experiments examined whether replacement therapy with recombinantly derived bovine somatotropin (rbST) would induce puberty in heifers that had been actively immunized at 6 mo of age against growth hormone-releasing factor (GRF). Heifers received daily i.m. injections of 25 mg of rbST (Exp. 1, n = 6; Exp. 2, n = 4) or vehicle (VEH; Exp. 1, n = 6; Exp. 2, n = 4) for 56 d. Serum concentrations of somatotropin (ST, nanograms/milliter) were low in all heifers before first injection in Exp. 1 (1.56 +/- .04) and 2 (.95 +/- .03). During treatment, serum ST was greater (P < .01) in rbST than in VEH heifers (75.4 +/- 4.8 vs 2.8 +/- .1 ng/mL, respectively) in both experiments and remained increased through d 57 (32.2 +/- 6.4 vs .90 +/- .01 ng/mL). IN Exp. 1 and 2, concentrations of serum IGF-I were similar in rbST and VEH heifers before treatment, increased (P < .01) 12 h after first rbST, and remained increased (P < .01) through d 57 in rbST heifers. Concentrations of serum insulin (INS) and plasma glucose (GLU) were similar (P > .10) in rbST and VEH heifers before first injection (Exp. 1 and 2). Serum INS (micro-units/milliliter) was greater (P < .01) in rbST (61.7 +/- 3.7 and 36.0 +/- 2.4) than in VEH (12.4 +/- 1.6 and 8.1 +/- 1.0) heifers on d 1 or 2 only, in Exp. 1 and 2, respectively. In Exp. 1, GLU was increased (P < .05) by rbST on d 2 through 57, but only on d 1 in Exp. 2. Proportion of heifers pubertal by d 21 tended to be greater (P < .07) in rbST (3 of 6) than in VEH (0 of 5) heifers in Exp. 1, but not in Exp. 2 (1 of 4 vs 1 of 4, respectively). All heifers in Exp. 1 and 50% of the heifers in Exp. 2 attained puberty by d 56. Daily rbST increased ST, IGF-I, INS, and GLU but did not hasten onset of puberty in heifers immunized against GRF.

Animals↗

Effect of recombinant bovine somatotropin (somidobove) in a sustained release vehicle on plasma somatotropin level and lactational performance of dairy cows.

The effects of administration of recombinantly derived bovine somatotropin (somidobove) in a sustained-release vehicle on the profiles of concentrations of bovine somatotropin (bST) in the blood plasma and on the milk yield of dairy cows of three herds were examined. Cows (36-87 days post partum) were treated subcutaneously with recombinant bST at 28-day intervals. In control animals, basal concentrations of bST averaged 1.4 ng.ml-1 in first-calf heifers and 1.5 ng.ml-1 in multiparous cows. In somidobove treated first-calf heifers, the concentration of bST was increased to 10.7, 14.5, and 27.0 ng.ml-1 at 24 h postinjection and in multiparous cows to 6.6, 11.0, and 11.7 ng.ml-1 on day 2 postinjection of 320, 640, and 960 mg of somidobove, respectively. On day 8 postinjection the average plasma bST levels of both parity groups are similar (on the average 3.4, 8.6, and 12.5 ng.ml-1 for three doses of somidobove respectively) and for the two highest doses being still significantly increased. During the 2nd week postinjection plasma bST concentration declined returning to control levels on day 15 postinjection. Somidobove-treated first-calf heifers produced 10.9, 16.7 and 17.9% and multiparous animals 25.5, 24.2 and 32.5% more milk than the controls when given 320, 640 and 960 mg somidobove, respectively. The cyclic pattern in milk yield within each 28-day injection interval was observed consistently in all herds. The milk yield increased to a maximum between day 4 to 8 postinjection and then slowly declined. Milk composition was not affected by somidobove treatment.

Animals↗

Impact of bovine somatotropin administration beginning at day 70 of lactation on serum metabolites, milk constituents, and production in cows previously exposed to exogenous somatotropin.

Metabolic and production responses are reported for 72 cows treated with bovine somatotropin (BST) for 30 days starting at day 70 of lactation. Of these 72 cows, 48 had been exposed in the preceding lactation to long-term treatment with BST at 3 dosages and 24 (controls) had not been given BST. Approximately half of the cows in each group were parity-2 cows, the rest were older. Comparisons between groups were made separately for parity-2, and older cows. Analyses, using pretreatment values of each variable as a covariate, indicated that older cows, but not parity-2 cows, significantly (P less than 0.05) increased milk production during treatment. Parity-2 cows, however, had a significantly higher milk fat percentage than controls following treatment. Cows treated with 51.6 or 86 mg BST/d in both parity groups had significantly higher serum-free fatty acids than controls. Estimated net energy balances were significantly lower for older treated cows, but did not significantly differ from controls for parity-2 treated cows. Older cows in the 86 mg of BST/d group tended to have higher concentrations of blood glucose than did older control-group cows. Treatment with BST did not significantly increase serum ketone concentrations in any group of animals, and none of the cows developed clinical ketosis during this period. Estimated net energy balance (ENEB) during treatment was a significant (P less than 0.05) covariate for free fatty acid concentrations in older cows and for milk fat percentage in parity-2 cows. Covariate adjusted analyses, using ENEB during treatment as a covariate, indicated that lipolytic stimuli already acting may be enhanced by treatment with BST, but a negative energy balance was not a necessary precondition for free fatty acid concentrations to increase following somatotropin treatment. Similarly, milk fat percentages for parity-2 treated cows were significantly (P less than 0.05) higher during treatment than controls when ENEB during treatment was used as a covariate. Increased milk fat concentrations in parity-2 treated cows were not associated with significant increases in the ratio of C18:C4-10 milk fatty acids, indicating that increased milk fat resulted from either an increase in incorporation of C18 fatty acids into milk fat coupled with an increase in de novo mammary synthesis of C4-10 milk fatty acids or an increase in C12-16 fatty acids that may arise either from increased tissue mobilization, from diet, or from de novo mammary synthesis.

Animals↗

[Results of the treatment of growth hormone deficiency with methionine-somatotropin or recombinant somatotropin].

Sixteen children with hGH deficiency were treated for a year with methionyl-somatotropin (Somatonorm) or recombinant-somatotropin (Genotropin). The hormone was administrated subcutaneously 3 time/week, 0.45-0.6 IU/kg/week. After a year of treatment, the mean growth rate in those who received Somatonorm increased from 3.96 +/- 0.8 cm/yr to 9.08 +/- 2.7 cm/yr, and in those who received Genotropin from 3.6 +/- 0.6 cm/yr to 8.58 +/- 1.1 cm/yr with no significant difference. No adverse effects were observed, but four children that received Somatonorm developed antihGH antibodies with a very low binding capacity, of less than 0.1 mg/L. All the children that received Genotropin were negative for antihGH antibodies.

Adolescent↗

The effect of bovine somatotropin and diet on somatotropin binding sites in hepatic tissue of lactating dairy cows.

In the lactating cow, galactopoiesis is stimulated by treatment with recombinant bovine somatotropin (bST) and by an improved plane of nutrition. The present study determined the interaction between these variables and examined whether a positive galactopoietic effect was accompanied by a change in hepatic binding sites for bST. Lactating dairy cows received one of three diets with increasing nutrient density; diet 1, 150 g/kg of dry matter (DM) of crude protein (CP) and 10.5 MJ/kg of DM of metabolizable energy; diet 2, 170 g/kg of DM of CP and 11.3 MJ/kg of DM of metabolizable energy; and diet 3, 190 g/kg of DM of CP and 12.1 MJ/kg of DM of metabolizable energy. At 90 d after calving, half of the cows in each dietary group were treated with bST every 14 d for the rest of the lactation. Both nutrient density and administration of bST increased milk yield significantly in mid and late lactation; there was no significant treatment by diet interaction. Treatment with bST significantly increased plasma concentrations of insulin-like growth factor (IGF)-I compared with IGF-I concentrations in controls in both mid and late lactation. Comparisons within diet revealed that concentrations of IGF-I were significantly higher in cows fed diet 3 than in cows fed diets 1 and 2 at both stages of lactation. Increases in plasma insulin were confined to cows in late lactation, and no changes were observed for nonesterified fatty acids. Liver biopsies showed that concentrations of hepatic binding sites for bST were not affected significantly by bST treatment but were increased in midlactation for cows fed diet 3. Concentration of hepatic binding sites per unit weight of tissue were greater for cows in midlactation than for cows in late lactation. In summary, exogenous bST treatment and increased nutrient density were associated with elevated plasma IGF-I concentrations and increased milk yield; however, only nutrient density in midlactation increased the number of hepatic binding sites for bST. Exogenous bST treatment had relatively little effect on the concentration of hepatic bST receptors compared with nutrient density.

Analysis of Variance↗

Somatotropin and insulin-like growth factor-I concentrations in plasma and milk after daily or sustained-release exogenous somatotropin administrations.

Effects of daily injectable or sustained-release bovine somatotropin (bST) administrations on plasma and milk bST and insulin-like growth factor-I (IGF-I) concentrations were monitored in 74 lactating cows through early, mid- and late lactation. Treatments beginning at wk 4 of lactation were excipient (CO, 24 cows) at 2 wk intervals, daily injections of 10.3 mg bST (DI, 25 cows) and 350 mg sustained-release bST at 2 wk intervals (SR, 25 cows). The duration of treatments was 40 wk. Data were first analyzed for the overall mean concentrations covering the 40 wk treatment period. Overall mean plasma bST, milk bST and plasma IGF-I concentrations were significantly increased by both bST treatments (p < 0.05). On the other hand, milk IGF-I concentrations were significantly increased (p < 0.05) only in the DI group. Next, data were analyzed according to stage of lactation. The bST treatments resulted in significant increases (p < 0.05) in plasma and milk bST concentrations for all early, mid- and late lactation periods. Even though plasma IGF-I concentrations were higher (p < 0.05) in all lactation periods for bST treatment groups, higher milk IGF-I concentrations (p < 0.05) occurred only in mid- and late lactation periods for the DI group. The patterns of bST and IGF-I concentrations in milk follows those of the plasma after bST treatments.

Animals↗

Changes in serum somatotropin, somatotropin mRNA, and serum and follicular insulin-like growth factor-I in response to feed restriction in cows actively immunized against growth hormone-releasing factor.

Cyclic cows immunized against growth hormone-releasing factor (GRFi, n = 19), human serum albumin (HSAi, n = 10), or not immunized (CON, n = 18) were used to investigate the effects of feed restriction on serum and pituitary somatotropin (ST), pituitary ST mRNA, and serum and follicular IGF-I. Cows were either fed 2.7 kg/d cottonseed hulls (R) or given ad libitum access to feed (AL) for 15 d. Ovaries bearing the largest follicle and pituitaries were collected on d 14, at 44 to 45 h after injection of prostaglandin F2 alpha. Data from CON and HSAi cows were similar; thus, data were combined (represented as CON). Serum ST (nanograms/milliliter) on d 13 was greater (P < .09) in CON-R (5.3) than in CON-AL (3.9), whereas ST in GRFi-AL (1.1) and GRFi-R (1.1; pooled SE = .4) were similar. Hemipituitary weight (grams) and ST mRNA (arbitrary units) were greater (P < .05) in CON (1.5 +/- .1 and 135 +/- 25) than in GRFi (1.0 +/- .1 and 90 +/- 18) cows. Across immunization, ST mRNA and pituitary ST concentration (mg/100 mg of tissue), respectively, were greater (P < .06) in R (152 +/- 22 and 22.5 +/- 1.9) than in AL (73 +/- 16 and 17.3 +/- 1.8) cows. Immunization and diet decreased (P < .05) serum IGF-I (nanograms/milliliter) on d 13 (CON, 176 +/- 7 vs GRFi, 42 +/- 8; AL, 120 +/- 7 vs R, 98 +/- 8). Concentrations of IGF-I in follicular fluid (FFL) from the largest follicle were lower in GRFi (29 +/- 3) than in CON (102 +/- 6) cows; however, IGF-I in FFL was similar in AL (70 +/- 9) and R (71 +/- 10) cows. In conclusion, GRFi decreased serum ST and IGF-I, and decreased ST mRNA. Feed restriction increased serum ST and ST mRNA, and decreased serum IGF-I. Although feed restriction and GRFi decreased serum IGF-I, concentrations of IGF-I in FFL were decreased only by GRFi.

Animals↗

Pulsatile release of somatotropin related to meal feeding and somatotropin response to secretagogues in horses.

Our goal was to establish a time of day and(or) interval from feeding that would avoid the refractory period after a somatotropin (ST) surge and optimize the responsiveness of horses to ST secretagogues. Two experiments were conducted with eight geldings conditioned to consume grain at 0800 and 1600 daily. In Exp. 1, during a 24-h period, these geldings averaged 3.2 +/- .3 pulses of ST with peak amplitude of 4.2 +/- .4 ng/mL, pulse duration of 55 +/- 6 min, and interpeak interval of 400 +/- 57 min. No ST peaks occurred within 2 h after either grain feeding. In Exp. 2, eight geldings were given 50 micrograms of ST-releasing factor (STRF) at 0800. Two geldings that had a pulse of ST between 0700 and 0800 failed to respond to STRF, but the other six responded with a pulse of ST at 37 +/- 3 min; peak amplitude was 4.6 +/- 2.2 ng/mL and duration was 123 +/- 25 min. Experiments 3 and 4 were with mares aged 20 to 26 yr and conditioned to be fed grain at 0800 daily. In Exp. 3, blood was sampled for 8 h beginning at 0500. Seven of the eight mares had a ST pulse in progress at 0500. Five additional pulses were detected, all from 0740 to 0940, but none from 0600 to 0700 or from 1000 to 1300. In Exp. 4, four of the same eight mares were given 50 micrograms of STRF at 0700 and the other four at 1300. Three of the four treated at 0700 and all four treated at 1300 responded to STRF with ST peaks at 20 +/- 5 min; peak amplitude was 12.7 +/- 9.5 ng/mL and duration was 69 +/- 6 min. In Exp. 5, nine mares aged 20 to 26 yr were fed grain at 0800 and 1600 as in Exp. 1 and 2 and given a nonpeptidal ST secretagogue (STS, Merck L-163,255) i.v. at 0, 1, or 5 mg/kg (n = 3 mares/dose) at 1300. No mare had a pulse of ST during the 1 h before treatment. All six mares given STS responded with ST pulses. The ST responses to STS at 1 and 5 mg/kg did not differ (P > .05); time to ST peak was 35 +/- 4 min, pulse amplitude was 24.0 +/- 6.3 ng/mL, and pulse duration was 100 +/- 9 min. We conclude that mares and geldings fed grain once or twice daily usually have a period of 2 to 5 h after feeding with no ST pulses. When horses are fed grain at 0800, one may give a ST secretagogue at 1300 to avoid a refractory period and improve the probability of an ST response.

Aging↗

Effects of recombinant equine somatotropin on wound healing, carbohydrate and lipid metabolism, and endogenous somatotropin responses to secretagogues in geldings.

The primary purpose of this experiment was to assess the possible beneficial effects of recombinant equine somatotropin (reST) administration on wound healing in adult geldings. The effects of the 21-d reST treatment on carbohydrate and lipid metabolism and on endogenous ST characteristics were monitored as well. Single, full-thickness skin incisions (7.62 x 7.62 cm) were made in the pectoral region of all geldings on d 0. Treated geldings received reST at 20 microg/kg BW i.m., and control geldings received vehicle (10 mM sodium borate) at equivalent volumes daily from d 0 (immediately after surgery) through d 20. Tracings of the wounds were made with acetate transparencies, and wound areas were calculated via a digital analyzer. In addition to once-daily blood samples collected at specified days throughout the treatment period, an i.v. glucose tolerance test was performed on d 16, and three assessments of endogenous ST secretion were performed in the 2 d immediately following the end of treatment: epinephrine administration during the morning of d 21, an exercise test during the afternoon of d 21, and i.v. aspartic acid infusion on d 22. There was no effect (P > . 1) of reST treatment on wound healing as assessed by changes in wound areas. Daily plasma ST, IGF-I, glucose, and insulin concentrations were higher (P < .05) and urea-nitrogen concentrations were lower (P < .001) in geldings receiving reST relative to controls. Glucose, NEFA, and insulin concentrations were all higher (P < .01) in reST-treated geldings before glucose infusion on d 16, and the responses to glucose were greater (P < .05) as well. Epinephrine administration increased (P < .02) ST concentrations in control geldings on d 21 but not in reST-treated geldings; a similar suppressive effect of reST treatment was observed for the ST response to exercise (P < .001). After aspartic acid infusion on d 22, reST-treated geldings had a much smaller (P < .001) ST response than did control geldings. In conclusion, reST administered to geldings at 20 microg/kg BW i.m. caused hyperglycemia, hyperinsulinemia, insulin insensitivity, mobilization of fatty acids, and an apparent negative feedback on the pituitary's ST response to various stimuli known to induce ST secretion. However, there was no beneficial effect of reST treatment with the wound model used in this experiment.

Animals↗